Guide price only. Final cost is confirmed after assessment.
Ostenil Injection offers a cutting-edge approach to managing joint pain associated with osteoarthritis. At London Cartilage Clinic, we utilise this hyaluronic acid-based treatment to provide relief and improve joint function for our patients, ensuring an enhanced quality of life.
Ostenil replenishes hyaluronic acid in arthritic joints to improve lubrication, absorb load, and reduce painful friction during movement.
It is typically considered as part of an overall osteoarthritis management strategy including activity modification and rehabilitation.
The value of Ostenil depends on precise indication and injection technique. Our team focuses on making sure the right patient receives the right product at the right time.
At London Cartilage Clinic, Ostenil is delivered within a comprehensive joint-care pathway focused on practical pain relief, function, and long-term joint preservation.
The relief from Ostenil Injection can last for several months, varying from patient to patient. Its long-lasting effect is one of the key benefits of this treatment.
Ostenil Injection is effective in various joints affected by osteoarthritis, not just the knee. It’s important to consult with our specialists to determine the best treatment plan for your condition.
Ostenil Injection is generally well-tolerated, with minimal risks. Any potential side effects or concerns can be discussed during your consultation with our experts.
Still have more specific concerns?
Free Discovery CallLondon Cartilage Clinic
Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.
ChondroFiller injection has produced no serious adverse effects across 19,000+ clinical cases since 2013; the complaint rate stands at 0.06%, among the lowest in cartilage repair. Post-injection swelling, pain, and stiffness resolve within 48–72 hours, but follow-up data beyond three years remain sparse.
In roughly half of ACL ruptures, articular cartilage sustains damage at the moment of rupture. The joint's inflammatory cascade thereafter actively degrades cartilage matrix, which cannot self-repair; this initiates osteoarthritis typically a decade earlier than in uninjured peers.
Functional recovery from ChondroFiller outpaces structural repair: patients achieve a clinically meaningful 30-point IKDC improvement within twelve months, but cartilage maturation on MRI continues beyond that functional plateau.
